logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yuki Takeyasu

Kansai Medical University
H指数:10
被引数:1,184

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical trajectory of KRAS G12C-mutated advanced non-small cell lung cancer: a single-center cohort study in Japan

KRAS G12C突变型晚期非小细胞肺癌的临床轨迹：一项日本单中心队列研究

Respiratory Investigation
IF2
2026-05-010
PRE
Okazaki, Yuta; Yoshioka, Hiroshige; Ikoma, Tatsuki; Araki, Keigo; Makihara, Natsuno; Kitagawa, Mai; Nagata, Yutaro; Fujii, Kazuki; Okuno, Yukiko; Kamisako, Keisuke; Nakanishi, Kentaro; Ikeda, Yume; Yoshida, Kiyori; Nakahama, Kahori; Takeyasu, Yuki; Katsushima, Utae; Yamanaka, Yuta; Ikeda, Satoshi; Kurata, Takayasu
Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study

奥希替尼单药作为表皮生长因子受体突变阳性非小细胞肺癌一线治疗诱导的危及生命肺炎：一项回顾性病例系列研究

Anticancer Research
IF1.7
2026-05-010
PRE
Nojiri, Takashi; Omura, Akiisa; Nishimura, Hiroshi; Uda, Hiroshi; Katayama, Michihito; Iede, Kiyotsugu; Takeyasu, Yuki; Katsushima, Utae; Okada, Hiroshi; Higashiyama, Masahiko
Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology

为什么选择Cemiplimab？在PD-L1表达超高水平且伴有鳞状组织学的非小细胞肺癌一线治疗中定义一个独特的治疗定位

Cancers
IF4.4
2026-01-170
OAAI
Satoshi Ikeda; Keigo Araki; Mai Kitagawa; Natsuno Makihara; Yutaro Nagata; Kazuki Fujii; Kiyori Yoshida; Tatsuki Ikoma; Kahori Nakahama; Yuki Takeyasu; Utae Katsushima; Yuta Yamanaka; Takayasu Kurata
Combined effects of slow movement training with tonic force generation and aerobic exercise prior to cancer therapy in patients with lung cancer (START-lung): a pilot feasibility trial

肺癌患者癌症治疗前的慢速运动训练与持续力量生成及有氧运动的联合效应（START-lung）：一项可行性试点试验

BMC Cancer
IF3.4
2025-10-030
OAAI
Utae Katsushima; Takuya Fukushima; Jiro Nakano; Kazuki Fujii; Yutaro Nagata; Keisuke Kamisako; Yukiko Okuno; Kiyori Yoshida; Tatsuki Ikoma; Yuki Takeyasu; Yuta Yamanaka; Hiroshige Yoshioka; Takayasu Kurata; Eisuke Ochi
Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study)

开放标签前瞻性II期研究方案：Durvalumab联合卡铂和足叶乙苷治疗晚期大细胞神经内分泌肺癌（LOGIK2401：NECTAR研究）

CANCER TREATMENT AND RESEARCH COMMUNICATIONS
IF0
2025-10-010
OAAI
Ishii, Hidenobu; Azuma, Koichi; Kiyomi, Fumiaki; Yoshimine, Kohei; Uchida, Kazuki; Tobino, Kazunori; Yamada, Tadaaki; Iwasa, Tsutomu; Kanemura, Hiroaki; Sumi, Toshiyuki; Iwama, Eiji; Mori, Masataka; Takenaka, Masaru; Takeyasu, Yuki; Kurata, Takayasu; Misono, Shunsuke; Tanaka, Kentaro; Okamoto, Isamu
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Ramucirumab与erlotinib联合作为携带<i>EGFR</i>外显子21 L858R突变的晚期或复发非小细胞肺癌的一线治疗：一项在日本进行的多中心回顾性观察队列研究（REAL-SPEED）。

Therapeutic Advances in Medical Oncology
IF4.2
2025-06-160
OA
Masashi Ishihara; Takahisa Kawamura; Yukiko Namba; Yuki Takeyasu; Yukihiro Hasegawa; Yuki Sato; Yoshiki Negi; Tomohiro Oba; Toshiyuki Sumi; Hirokuni Hirata; Hidemitsu Funabashi; Yuko Oya; Hajime Kikuchi; Naoko Katsurada; Takeshi Nakatani; Keiko Tanimura; Taku Nakagawa; Naoya Takeda; Takahiro Asami; Osamu Honjo; Hiromi Nagashima; Takumi Yamaura; Norihiko Hata; Miyako Kitazono; Naoya Nishioka; Akihiro Tamiya; Yuichi Sakamori; Ryota Shigaki; Kyoichi Kaira; Ryoichi Honda; Takashi Matsui; Eriko Suzuki; Kentaro Ito; Kojiro Otsuka; Naoto Takase; Yusuke Murakami; Kazuhiko Matsuno; Sumito Inoue; Akira Kisohara; Sojiro Kusumoto; Hiroe Aoshima; Yumiko Kakizaki; Akihito Kubo; Akito Hata; Nobuhisa Ishikawa; Kosuke Hamai; Nobuhiro Kanaji; Toshihiro Misumi; Noriyuki Matsutani; Nobuhiko Seki
Ramucirumab plus Erlotinib (RAM plus ERL) for advanced non-small cell lung cancer (NSCLC) harboring EGFR L858R mutation (L858R mut): A multicenter retrospective observational cohort study (REAL-SPEED)

Ramucirumab联合Erlotinib（RAM plus ERL）用于携带EGFR L858R突变（L858R mut）的晚期非小细胞肺癌（NSCLC）：一项多中心回顾性观察队列研究（REAL-SPEED）。

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Ishihara, M.; Kawamura, T.; Nanba, Y.; Takeyasu, Y.; Hasegawa, Y.; Sato, Y.; Negi, Y.; Oba, T.; Sumi, T.; Hirata, H.; Funabashi, H.; Oya, Y.; Kikuchi, H.; Katsurada, N.; Nakatani, T.; Harada, T.; Misumi, T.; Matsutani, N.; Seki, N.

研究方向

暂未获取到该数据
Y
Yuichiro Ohe
H 指数:76论文数:958被引数:4.1万
Y
Yasushi Goto
H 指数:41论文数:483被引数:8,659
T
Tatsuya Yoshida
H 指数:32论文数:374被引数:7,728
H
Hidehito Horinouchi
H 指数:38论文数:430被引数:5,780
Y
Yuji Matsumoto
H 指数:27论文数:231被引数:2,559
Y
Yusuke Okuma
H 指数:30论文数:397被引数:4,126
N
Noboru Yamamoto
H 指数:66论文数:1,329被引数:1.8万
K
Ken Masuda
H 指数:22论文数:204被引数:2,628
Y
Yuki Shinno
H 指数:19论文数:132被引数:1,934
Y
Yuta Yamanaka
H 指数:9论文数:79被引数:226